Microbot Medical Inc MBOT 深 滬
等待開盤 10-17 09:30:00 美东时间
2.84
-0.080
-2.74%
華盛通- 最 高3.03
- 今 開2.93
- 成交量 207.11万股
- 最 低 2.805
- 昨 收 2.92
- 總市值 1.03亿
- 52周最高 4.67
- 市盈率 靜 --
- 換手率 5.69%
- 52周最低 0.89
- 委 比 99.49%
- 總股本 3637.78万
- 歷史最高 149.10
- 量 比 0.70
- 振 幅 7.71%
- 歷史最低 0.82
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
Microbot Medical Inc. will exhibit its LIBERTY® Endovascular Robotic System at the upcoming CIO symposium in Miami, marking its first commercial presence post-FDA clearance. The company has completed its commercial leadership team recruitment, with Justin Bourne, Dani Kulp, and Xiomara Ortiz joining to support the launch. The LIBERTY® System is set to commence its limited market release during Q4 2025, following successful logistics preparation.
10-16 12:30
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Microbot Medical Partners With U.S. Based 3PL Company To Support Commercialization Of FDA-Cleared LIBERTY System
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 This
10-14 20:32
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
Microbot Medical Inc. partners with a U.S. 3PL company to support the commercialization of its FDA-cleared LIBERTY® Endovascular Robotic System. The limited market release is expected in Q4 2025, with a broader launch planned for April 2026. The partnership aims to enhance inventory management and customer support, leveraging the logistics provider’s expertise in the medical device industry. The company is focused on efficiently executing its go-...
10-14 12:30
Microbot Medical Announces Series H Options Exercise
The latest update is out from Microbot Medical ( ($MBOT) ). On September 29, 20...
10-04 04:59
Microbot Medical Announces That The Japanese Patent Office Has Granted The Company Its First Patent In Japan, Covering The Core LIBERTY System Technology
Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing as Global
10-01 21:14
Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
Microbot Medical Inc. has announced that the Japanese Patent Office has granted its first patent in Japan for the core technology of the LIBERTY® Endovascular Robotic System. The company has also received patents in the U.S., China, and Israel over the past 90 days. The FDA granted marketing clearance for the LIBERTY® System on September 8, 2025, and the company is accelerating its commercial launch in the U.S., targeting an estimated 2.5 million...
10-01 13:00
Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. (NASDAQ: MBOT) announced that its CEO, Harel Gadot, will be interviewed on Benzinga All Access at 10:45am ET on September 24, 2025. The interview will focus on the recent FDA clearance of the LIBERTY® Endovascular Robotic System and the company's commercialization plans in the U.S. Microbot Medical is a medical device company specializing in robotic technology for endovascular procedures, offering advanced solutions for prec...
09-23 12:30
Microbot Medical Awards Bonuses Amid Restructuring
Microbot Medical ( ($MBOT) ) has provided an announcement. On September 17, 202...
09-20 05:03
Microbot Medical Secures $25.2M in New Funding Round
The latest update is out from Microbot Medical ( ($MBOT) ). On September 14, 20...
09-17 05:30
